Stay updated with breaking news from Servier Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
With over 30 years of industry experience, the former Global Head of Licensing at Servier Group will spearhead LabGenius' business development, commercial strategy, and operational delivery. LabGenius
Share this article Share this article BOSTON, May 5, 2021 /PRNewswire/ -- Servier Pharmaceuticals, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for TIBSOVO (ivosidenib tablets) as a potential treatment for patients with previously treated IDH1-mutated cholangiocarcinoma. The sNDA was granted Priority Review, which accelerates the review time from 10 months to a goal of 6 months from the day of filing acce...
Share: Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene's Proprietary Lymphodepletion Regimen ALLO-501A, Intended for a Potentially Pivotal Phase 2 Trial, Previously Granted FDA Fast Track Designation for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Allogene to Host Virtual CD19 Forum to Review ASCO Datasets on May 19, 2021 at 2:30 p.m. PT/5:30 p.m. ET SOUTH SAN FRANCISCO, Calif. and PARIS, April 28, 2021 (GLOB...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in ... Allogene Therapeutics, Inc.April 28, 2021 GMT Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene’s Proprietary Lymphodepletion Regimen ALLO-501A, Intended for a Potentially Pivotal Phase 2 Trial, Previously Granted FDA Fast Track Designation...
Press release content from Business Wire. The AP news staff was not involved in its creation. Servier Earns the Best Place to Work Certification in Ukraine For 2021 April 14, 2021 GMT KYIV, Ukraine--(BUSINESS WIRE)--Apr 14, 2021-- Servier Ukraine LLC, a subsidiary of Servier, a global pharmaceutical group governed by a Foundation, has been recognized as one of the best places to work for in Ukraine. The certification process consisted of an employee assessment survey conducted among Servier Ukraine employees along with an HR Assessment evaluating people practices implemented within the organi...